Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

The Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA transcatheter heart valve system is indicated for use in patients with heart disease due to native calcific aortic stenosis at any ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial ...

First to share a program update was Pradeep Yadav, MD, of Piedmont Heart Institute in Atlanta, who described the latest addition to the Sapien line of balloon-expandable valves: Sapien X4.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by ...

Patients in the balloon-expandable valve group were treated with the Sapien 3 Ultra valve. The first co-primary outcome (death, stroke, or heart failure hospitalization) at 12 months was 9.4% in the ...

At 1 year, the combined rate of all-cause mortality, stroke, or rehospitalization was 16.16% in patients treated with Acurate neo2 and 9.53% among those treated with valves from the Evolut (Medtronic) ...

Post-procedural complications such as pacemaker dependency remain a concern, particularly after TAVR with certain valve models. A comparison between the Portico and Edwards Sapien 3 valves in TAVR ...

versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system, selected at the discretion of the implanting physician.

versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system. The composite rate of all-cause mortality, stroke, or ...

However, the firm’s outsized reliance on heart valves is the key factor that has kept us from tipping the firm into wide moat territory. Edwards Lifesciences Prepares for Stronger Sapien Growth ...